PEP

Business profile & competitive position

PepsiCo, Inc. operates in the Consumer Defensive sector under the Beverages – Non-Alcoholic industry classification. That means its core business is selling everyday beverage brands to consumers, a category where demand is relatively stable and repeat-purchase habits dominate. The company’s current financial footprint includes a $191.4 billion market capitalization and a 50.6% return on equity, which points to strong capital efficiency in converting shareholder equity into profit. Its 11.1% net margin further suggests PepsiCo retains meaningful pricing power and scale advantages, though it is not immune to cost pressure. A beta of just 0.36 confirms the defensive label: the stock historically moves much less than the overall market, consistent with a mature staples business.

Interpreting those numbers for competitive moat: a net margin above 10% and an ROE near 50% are hallmarks of a business with durable brand equity and distribution reach. In non-alcoholic beverages, shelf-space access, marketing scale, and entrenched consumer habits create meaningful barriers for new entrants. That said, the same numbers also signal a business that is already highly optimized; future gains depend more on mix, volume, and cost control than on explosive new-market expansion.

Financial posture

As of the snapshot, PepsiCo trades at $140.42, roughly 5% above its 50-day EMA of $133.79, with an RSI of 66.0. The RSI is flirting with overbought territory but has not crossed the common 70 threshold. The P/E ratio sits at 17.6, which places the stock in a moderate valuation zone for a large defensive consumer staple. The $191.4 billion market cap reflects PepsiCo’s standing as one of the largest players in its category.

Profitability metrics reinforce a high-quality profile. The 11.1% net margin shows that, after all costs, PepsiCo keeps about eleven cents of profit on every dollar of sales, while the 50.6% ROE indicates it is highly effective at generating returns from its equity base. Because the company’s beta is 0.36, much of its risk profile is tied to interest-rate sensitivity and consumer-staples flows rather than cyclical volatility. Together, these figures paint a picture of a large, profitable, low-volatility business priced at a market-average to modest premium multiple.

Macro & geopolitical exposure

Because PepsiCo sits in Beverages – Non-Alcoholic, its macro exposures are largely those affecting the broader beverage and packaged-food space. Input costs—sugar, high-fructose corn syrup, aluminum, plastic resin, and freight—are persistent variables. Inflationary pressure or supply-chain disruption can compress margins unless price hikes or productivity savings fully offset them. The industry is also exposed to trade policy, especially tariffs on aluminum and other packaging materials, which directly affect can costs.

Regulatory risk is another staple-sector feature. Soda taxes, sugar-content limits, nutrition-labeling rules, and restrictions on marketing to children can affect demand or profitability in key markets. Currency translation matters too: PepsiCo is a global consumer company, so dollar strength can dampen reported overseas revenue.

More recently, health-and-wellness trends have reshaped demand within the category. The 2026 news flow around employers dropping GLP-1 weight-loss drug coverage, while Medicare may cover certain GLP-1 treatments for sleep apnea or heart risk starting at age 65, adds another layer. Any sustained shift in consumer eating and drinking behavior tied to weight-management drugs could influence volumes for sugary or snack-adjacent beverages. These themes are not company-specific forecasts; they are macro and health-policy currents that naturally touch a non-alcoholic beverage giant.

Recent developments

The most recent news cycle has been dominated by dividend and health-care themes rather than by a new product launch or acquisition. On November 2, 2026, 247wallst.com reported that Pepsi, Starbucks, and Cigna are dropping GLP-1 coverage, while noting that Medicare may cover Zepbound for sleep apnea or Wegovy for heart risk at age 65, with Part D spending capped at $2,400 in 2027. That headline is relevant because it highlights employer cost-cutting dynamics that could alter how consumers use weight-management drugs, with possible spillover effects on beverage consumption patterns over time.

On the same day, 247wallst.com also published “3 Blue Chip Dividend Stocks That Out-Yield the 2027 COLA,” a story that places PepsiCo in a dividend-income context. A day earlier, 247wallst.com ran “4 Blue-Chip Dividend Stocks That Kept Raising Payouts Through 2008 and 2020,” underscoring the stock’s recurring appearance in conversations about recession-resistant dividend growth. Finally, on fool.com on November 1, 2026, a story titled “This Dividend Stock Yielding Quadruple the S&P 500 Looks Like a Buy Right Now” again framed PepsiCo through an income prism. The clustering of these articles suggests the investment narrative around PepsiCo has recently tilted toward yield and defensive quality rather than aggressive growth.

Earnings behavior & post-earnings drift

PepsiCo has been a reliable earnings performer. Over the last eight reported quarters, the company beat expectations 7 out of 8 times, for an 88% beat rate. The average earnings surprise across those quarters was 1.7%. Despite that consistency, the average five-day price move following earnings has been only 0.5%, classified as “flat.” That pattern suggests beats are frequently already priced in, and the stock tends not to make large directional runs simply because it clears the consensus estimate.

The last four quarters illustrate the point. On October 8, 2026, PepsiCo reported EPS of $2.34 versus an estimate of $2.29, a 2.2% surprise. The stock fell 1.85% the next day and eked out a 0.03% gain over the following五天交易. On July 9, 2026, EPS came in at $2.20 against $2.19, a 0.5% beat; the stock dipped 0.35% the next session but gained 1.14% over the next five sessions. The April 16, 2026 release delivered $1.61 versus $1.54, a 4.5% surprise, yet the next-day reaction was -0.45% and the five-day drift was -1.69%. Only the February 3, 2026 report—a $2.26 print versus a $2.24 estimate, a 0.9% beat—brought a positive one-day move of 2.04% and a five-day gain of 2.53%.

The unofficial consensus for the next report, scheduled for February 2, 2027 before the market open, is $2.24. Given the stock’s tendency to beat but drift sideways, the market’s real expectation may be closer to a slight beat already embedded in the price rather than a make-or-break headline number.

For a deeper dive into how institutional analysts weigh these fundamentals, recent news, and the upcoming February report, readers should examine the full institutional verdict and consensus breakdown rather than relying on headline figures alone.